14 completed, 6 terminated, 5 recruiting, 4 unknown. 33 Phase 2, 6 Phase 3, 4 Phase 1.
Follow SOC: new trials by email Literature Review of SOC trials Research Report on SOC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors ARV-6723, Pembrolizumab, SOC - Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | Arvinas Inc. | 499 | 2026-07-29 | 2026-10-13 |
| Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies SERD* + abemaciclib, SERD* + everolimus, SERD* + everolimus or capecitabine - Breast Cancer, Metastatic Breast Cancer | Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 700 | 2026-02-16 | 2026-09-18 |
| LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer Exercise Therapy, Fasting-Mimicking Diet, SOC - Triple Negative Breast Cancer (TNBC), Early Setting | Phase 2 | Recruiting | Universitaire Ziekenhuizen KU Leuven | 356 | 2026-02-01 | 2026-08-07 |
| A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy VS-01 on top of SOC (Active Treatment Group), SOC - Hepatic Encephalopathy, Acute on Chronic Liver Failure (ACLF) | Phase 2 | Terminated | Genfit | 3 | 2025-08-25 | 2026-01-12 |
| Effect of Belimumab on Antibody Titers in Primary APS Patients Belimumab+SOC, SOC - Antiphospholipid Syndrome (APS) | Phase 2 | Recruiting | Ruijin Hospital | 20 | 2024-04-01 | 2024-12-24 |
| Effect of Telitacicept on Antibody Titers in Primary APS Patients Telitacicept+SOC, SOC - Antiphospholipid Syndrome (APS) | Phase 2 | Completed | Ruijin Hospital | 20 | 2023-12-01 | 2026-01-20 |
| Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment Serplulimab, SOC - Small-cell Lung Cancer | Phase 2 | Active not recruiting | Guangdong Association of Clinical Trials | 66 | 2023-07-07 | 2026-07-28 |
| Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors GTAEXS617, SoC - Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | 230 | 2023-07-06 | 2026-08-13 |
| Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Adult COVID-19 Patients With Comorbidities Ropeginterferon alfa-2b, SOC - COVID-19 | Phase 2 / Phase 3 | Unknown | National Taiwan University Hospital | 60 | 2023-05-15 | 2023-04-11 |
| A Study to Assess Safety, Efficacy, and Pharmacokinetics of INM004 in Pediatric Patients With STEC-HUS INM004, SoC - Diarrhea-Associated Hemolytic Uremic Syndrome, Pediatric Kidney Disease | Phase 2 | Completed | Inmunova S.A. | 57 | 2022-10-06 | 2023-08-21 |
| DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old Dolutegravir (DTG) and lamivudine (3TC), SOC - HIV Infections | Phase 2 / Phase 3 | Active not recruiting | PENTA Foundation | 386 | 2022-04-22 | 2026-03-04 |
| Study to Evaluate Efficacy and Safety of Switching to VM-1500A-LAI + 2NRTIs From the 1st Line Standard of Care Therapy VM-1500A-LAI, Standard of Care - HIV-1-infection | Phase 2 / Phase 3 | Unknown | Viriom | 438 | 2022-04-01 | 2022-01-24 |
| Investigating the Efficacy and Safety ICATIBANT For The Treatment of Patients With SARS-CoV-2 (COVID-19) Infection Firazyr, SoC - COVID-19 Pneumonia | Phase 2 | Completed | Sebastian Videla | 73 | 2021-04-12 | 2022-08-03 |
| Prevention and Treatment With Hydroxychloroquine + Azithromycin of Acute Respiratory Syndrome Induced by COVID-19 Hydroxychloroquine Pill + Azithromycin Pill, SOC - Acute Respiratory Distress Syndrome, Covid19 | Phase 2 | Unknown | Maimónides Biomedical Research Institute of Córdoba | 132 | 2021-02-10 | 2021-07-08 |
| Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19 Ruconest - Confirmed Coronavirus Disease | Phase 2 | Completed | Pharming Technologies B.V. | 38 | 2020-11-30 | 2024-02-16 |
| Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19 Silmitasertib, SOC - Covid19 | Phase 2 | Completed | Senhwa Biosciences, Inc. | 20 | 2020-11-30 | 2025-01-16 |
| Clinical Study for the Treatment With Interferon-ß-1a (IFNß-1a) of COVID-19 Patients Interferon-ß-1a, Standard of Care (SOC) - COVID-19 Virus Infection | Phase 2 | Terminated | Emanuele Bosi | 56 | 2020-11-02 | 2021-05-03 |
| A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients Bemcentinib, SoC - COVID-19 | Phase 2 | Completed | BerGenBio ASA | 115 | 2020-10-20 | 2024-10-16 |
| Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19 Oxytocin, Standard of Care - Covid-19, Corona Virus Infection | Phase 2 | Withdrawn | Azienda Ospedaliero-Universitaria di Parma | 2020-09-01 | 2021-01-14 | |
| A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19) PTC299, SOC, Placebo - Pneumonia, COVID-19 | Phase 2 / Phase 3 | Terminated | PTC Therapeutics | 189 | 2020-07-09 | 2023-06-26 |
Showing 20 of 33. Sign in to see all of them.
COVID-19 (8) · Triple Negative Breast Neoplasms (4) · Coronavirus Infections (3) · HIV Infections (3) · Antiphospholipid Syndrome (2) · Carcinoma, Non-Small-Cell Lung (2) · Pulmonary Arterial Hypertension (2) · Small Cell Lung Carcinoma (2) · Acute-On-Chronic Liver Failure (1) · Adenoviridae Infections (1) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1)
PENTA Foundation (3) · Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA (2) · Ruijin Hospital (2) · Arvinas Inc. (1) · Azienda Ospedaliero-Universitaria di Parma (1) · BerGenBio ASA (1) · ChronTech Pharma AB (1) · Cristina Avendaño Solá (1) · Emanuele Bosi (1) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. (1) · Genfit (1) · Guangdong Association of Clinical Trials (1) · Inmunova S.A. (1) · Jazz Pharmaceuticals (1) · Karyopharm Therapeutics Inc (1)
United States (12) · Spain (9) · France (7) · United Kingdom (7) · South Africa (5) · Germany (4) · Australia (3) · Belgium (3) · China (3) · Italy (3) · Portugal (3) · Thailand (3) · Uganda (3) · Argentina (2) · Brazil (2)
Alison Murray (1) · Anastasia Pokrovskaya, PhD (1) · Anders G Vahlne, Professor (1) · Ann Smeets, MD, PhD (1) · Antonio Ramos, MD, PhD (1) · Carla Greenbaum (1) · Chris P. Recknor, MD (1) · Christine Desmedt, PhD (1) · Christoph Bucher (1) · Diana Gibb (1) · Emanuele Bosi, Professor (1) · Erez V. Kachel, MD (1) · Eric Winer, MD (1)
PMID 27629486, PMID 32763217, PMID 33225960, PMID 33446115, PMID 33472681, PMID 33789009, PMID 34013969, PMID 34473652, PMID 34747368, PMID 34817414, PMID 34965338, PMID 35413921, PMID 35868341, PMID 36041750, PMID 36055295, PMID 36610464, PMID 36734509, PMID 37162745, PMID 37304494, PMID 37766218, PMID 37766505, PMID 37977903, PMID 38010606, PMID 38572639, PMID 38636725, PMID 39978387, PMID 40035659, PMID 41579881, PMID 41757982, PMID 42246435
2014 (1), 2017 (1), 2018 (1), 2025 (1)